CSI Market
Sign In | Register

United Therapeutics (UTHR) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access UTHR quarterly Cash Flow →
Changes in quarterly cash flow trends offer perspective on how United Therapeutics funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income1,334.70
Depreciation & amortization85.60
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets Held-for-use21.70
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-52.60
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Intangible Assets0.00
Share-based Compensation147.70
Income (Loss) from Equity Method Investments0.00
Loss Contingency, Loss in Period0.00
Provision For Doubtful Accounts And Inventory Writedown-
License Costs Incurred But Not Paid-
Impairment Of Investments In Privately Held Companies-
Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount-
Tangible Asset Impairment Charges-
Equity Securities Fv Ni Unrealized Gain Loss-
Income taxes97.70
Gain on Sale of Investments0.00
Increase (Decrease) in Accounts Receivable-70.90
Increase (Decrease) in Accounts Payable and Accrued Liabilities97.90
Increase (Decrease) in Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.00
Other Working Capital-80.90
Other Noncash Income (Expense)-19.70
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities1,561.20
Investing Activities
Capital Expenditures-526.00
Sale of Capital Items0.00
Short-term Investments Proceeds3,445.50
Payments to Acquire Available-for-sale Securities, Debt-3,405.40
Real Estate Investments0.00
Payments To Acquire Variable Interest Entity-
Advance Payment Related To Property Plant And Equipment-10.40
Decrease In Cash Due To Deconsolidation Of Variable Interest Entity-
Proceeds From Sale Of Equity Securities Fv Ni-
Proceeds From Equity Securities Without Readily Determinable Fair Value-
Payments To Acquire Equity Securities Without Readily Determinable Fair Value-55.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Long-term Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Payments to Acquire Equity Method Investments0.00
Sale of businesses0.00
Accounts payable0.00
Proceeds from Sale of Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-551.30
Financing Activities
Short-term debt Net-300.00
Other borrowing transactions-11.50
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-816.90
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-21.60
Payments Of Convertible Debt Hedge And Warrants Net-
Payment For Accelerated Share Repurchase Transaction Cost-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-1,150.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow1,035.20
Total Cash Flow-140.10
4 historic quarters locked

Sign in to unlock the full United Therapeutics cash flow history.

Sign In Create Free Account

About United Therapeutics Corp Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 25, 2026
  • Source: uthr-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001082554-26-000006

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License